Morning versus evening administration of estradiol to girls with turner syndrome receiving growth hormone: impact on growth hormone and metabolism. A randomized placebo-controlled crossover study.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

In order to test this hypothesis, a randomized double-blind placebo-controlled crossover study was conducted.

Why It Was Studied

Timing of 17beta-estradiol (E2) administration in relation to that of GH could influence the "first pass effect" of E2 on hepatic IGF-I secretion.

After each period, 24-h blood sampling was performed.

Who Took Part

By PubMed's age tags, the people studied were children, teenagers and adults, women only.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

In the crossover set-up each of the participants took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.

What Was Measured

PubMed files the paper under topics including Analysis of Variance, Area Under Curve, Blood Chemical Analysis, Estradiol, Glucose Tolerance Test, Growth Hormone and Insulin Resistance.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 1 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2001 (Acta paediatrica (Oslo, Norway : 1992)), a journal based in Norway.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.